Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Brain Neoplasms 3Neoplasm Metastasis 2Breast Neoplasms 2Sarcoma, Synovial 1Sarcoma 1Prostatic Neoplasms 1Oligodendroglioma 1Lung Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Gliosarcoma 1Glioma 1Glioblastoma 1Disease 1Dermatofibrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Astrocytoma 1

Interventions

Temozolomide 46Radiotherapy 36Bevacizumab 34Carmustine 13Erlotinib Hydrochloride 11Irinotecan 10sargramostim 7Thalidomide 7Chemotherapy, Adjuvant 7Carboplatin 7Radiation 6pembrolizumab 5Topotecan 5Magnetic Resonance Spectroscopy 5Filgrastim 5Drug Therapy 5Cyclophosphamide 5aldesleukin 4Tamoxifen 4Surgical Procedures, Operative 4Sorafenib 4O(6)-benzylguanine 4Gefitinib 4Etoposide 4Celecoxib 4cediranib 3Radiotherapy, Intensity-Modulated 3Radiotherapy, Conformal 3Peripheral Blood Stem Cell Transplantation 3Imatinib Mesylate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Gliosarcoma × Quality of Life × Clear all
NCT00667394 2015-11-05

Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
42 enrolled 11 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡